From Structure to Vulnerability: Mitochondrial Supercomplexes in Cancer Cells

TL;DR

This paper explores how mitochondrial supercomplexes help cancer cells adapt metabolically and survive stress, suggesting they could be targeted for cancer therapy.

Contribution

The paper identifies mitochondrial supercomplexes as a novel therapeutic target in cancer by linking their dynamics to metabolic flexibility and therapy resistance.

Findings

Mitochondrial supercomplexes enhance electron transport efficiency and regulate reactive oxygen species in cancer cells.

Supercomplex remodeling allows cancer cells to adapt to metabolic and environmental stress, supporting tumor growth.

Targeting supercomplex assembly or components could disrupt cancer metabolism and improve treatment outcomes.

Abstract

What are the main findings?
Mitochondrial respiratory supercomplexes (SCs) are dynamically organized assemblies regulated by membrane lipid composition and specific protein factors.SCs formation optimizes electron transfer efficiency and modulates mitochondrial reactive oxygen species production.

Mitochondrial respiratory supercomplexes (SCs) are dynamically organized assemblies regulated by membrane lipid composition and specific protein factors.

SCs formation optimizes electron transfer efficiency and modulates mitochondrial reactive oxygen species production.

What are the implications of the main findings?
Dynamic SCs remodeling contributes to mitochondrial adaptation under metabolic and environmental stress.In cancer, SCs dynamics support metabolic flexibility and redox homeostasis and may present therapeutic opportunities.

Dynamic SCs remodeling contributes to mitochondrial adaptation under metabolic and environmental stress.

In cancer, SCs dynamics support metabolic flexibility and redox homeostasis and may present therapeutic opportunities.

Mitochondrial respiratory supercomplexes are emerging as key regulators of bioenergetics, redox homeostasis, and metabolic plasticity in cancer. Their assembly enhances electron transport efficiency, limits reactive oxygen species production, and supports the high oxidative and biosynthetic demands of tumor growth. Cancer cells remodel supercomplex organization in response to hypoxia, nutrient limitation, and therapeutic stress, enabling rapid metabolic adaptation. Multiple assembly factors—including COX subunits, HIGD1A/2A, COX7A2L (SCAF1), cardiolipin remodeling enzymes, and Complex I assembly factors such as NDUFAF1 and NDUFAF2—contribute to supercomplex stabilization and can be dysregulated in malignancy. Alterations in these factors enhance respiratory flexibility and therapy resistance, particularly in aggressive tumors such as glioblastoma. However, critical gaps remain, including incomplete understanding of the molecular mechanisms controlling supercomplex assembly and remodeling, limited validation of functional findings in primary patient-derived cells or clinical samples, and uncertainty regarding the contribution of supercomplex to therapy resistance and metabolic adaptation across tumor types. Advances in structural biology and functional imaging have uncovered tumor-specific vulnerabilities within supercomplex architecture that may be exploited therapeutically. Targeting supercomplex assembly, cardiolipin–protein interactions, or electron flux through individual supercomplex modules represents a promising approach to disrupt cancer metabolism and sensitize tumors to treatment. This review synthesizes current knowledge on supercomplex regulation, function, and therapeutic potential in cancer, and outlines key unanswered questions that remain to be addressed.

Figures